Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a phase 1B/2 study.
Authors
Matasar, MHerrera, A
Kamdar, M
Mehta, A
Assouline, S
Fleury, I
Kim, T
Kim, W
Bosch, F
Radford, John A
Flowers, C
Bu, L
Hong, W
Sehn, L
Affiliation
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021Issue Date
2017